RxDoctor Payments Data

Imtiaz Ismail, MD

Interventional Cardiology · Sulphur Springs, TXNPI 1114369170

Payments from drug & device makers

$13,607in general payments, 2019–2025

Across 299 payments — averaging $45.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Medtronic$2K
  • Edwards Lifesciences$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Novartis$584
  • Shockwave Medical, Inc$552
  • plus $3K from 19 others

What the payments were for

  • Travel & lodging$5,80943%
  • Food & beverage$7,51455%
  • Education$2832%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,607 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$232,108
Medicare patients
1,779
Services billed
4,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban662$635,967
AdempasRiociguat13$169,289
EntrestoSacubitril/Valsartan122$139,064
XareltoRivaroxaban135$135,377
Repatha SureclickEvolocumab116$74,297
FarxigaDapagliflozin Propanediol51$55,212
JardianceEmpagliflozin54$53,218
Ranolazine ErRanolazine146$18,738
Metoprolol Succinate862$11,742
MultaqDronedarone Hcl13$9,372
Rosuvastatin Calcium584$8,606
Atorvastatin Calcium847$7,846
Ezetimibe279$4,566
Potassium Chloride265$4,476
VascepaIcosapent Ethyl12$3,896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$635,967662 claims
NovartisEntresto$584$139,064122 claims
Johnson & JohnsonXarelto$207$135,377135 claims
AstraZenecaFarxiga$315$55,21251 claims
Boehringer IngelheimJardiance$31$53,21854 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Sulphur Springs

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →